United States-based Senores Pharmaceuticals, Inc announced on Monday that it has launched its Nicardipine Hydrochloride Capsules USP, 20mg and 30mg, a bioequivalent and therapeutically equivalent to Chiesi USA's Cardene Capsules, 20mg and 30mg, in the United States.
Burel Pharmaceuticals, LLC is to market the product.
The product is indicated for the management of patienrs with chronic stable angina (effort-associated angina) and for the treatment of hypertension.
The company has received a Competitive Generic Therapy (CGT) designation for Nicardipine Hydrochloride Capsules USP, 20mg and 30mg. With this approval, the company is eligible for 180 days of CGT exclusivity upon commercial marketing.
Aveva Drug Delivery systems introduces generic Fentanyl Transdermal Patch in US
Independent Pharmacy Cooperative signs cooperation agreement with Legacy Pharmacy Group
ILIKOS Consulting partners with Jordan Center for Pharmaceutical Research
Axsome Therapeutics settles patent litigation with Teva over AUVELITY
Breckenridge Pharmaceutical's Everolimus Tablets for Oral Suspension receive US FDA approval
Newbury Pharmaceuticals secures generic approval for pomalidomide in Denmark
Newbury Pharmaceuticals secures generic approval for Bosutinib in Norway
Guangzhou Fermion Technology partners with Simcere Pharmaceutical